Evidence map›Paper›PMID 36332437›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2022

The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres.

Peter van Dam, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Cynthia Aristei, Laura Biganzoli, Maria J Cardoso, Kwok L Cheung, Giuseppe Curigliano, Jakob De Vries and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Peter van DamMultidisciplinary Oncologic Center, Antwerp University Hospital, Edegem, Belgium. Electronic address: peter.vandam@uza.be.
Mariano TomatisEuropean Society of Breast Cancer Specialists (EUSOMA), Florence, Italy.
Antonio PontiEuropean Society of Breast Cancer Specialists (EUSOMA), Florence, Italy; CPO Piemonte, Turin, Italy.
Lorenza MarottiEuropean Society of Breast Cancer Specialists (EUSOMA), Florence, Italy.
Cynthia AristeiRadiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital Sant'Andrea delle Fratte Perugia, Italy.
Laura Biganzoli"Sandro Pitigliani" Department of Medical Oncology, Hospital of Prato, Prato, Italy.
Maria J CardosoEuropean Society of Breast Cancer Specialists (EUSOMA), Florence, Italy; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
Kwok L CheungEuropean Society of Breast Cancer Specialists (EUSOMA), Florence, Italy; Academic Unit for Translational Medical Sciences, School of Medicine University of Nottingham, Royal Derby Hospital Centre, UK.
Giuseppe CuriglianoDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Italy.
Jakob De VriesUniversity Medical Center Groeningen, the Netherlands.
Donatella SantiniPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
Francesco SardanelliDepartment of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy; Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Isabel Teresa RubioBreast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Cancer Center Universidad de Navarra, Spain.
Eusoma Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe analysed the impact of the SARS-CoV-2 pandemic (COVID-19) on the quality of breast cancer care in certified EUSOMA (European Society of Breast Cancer Specialists) breast centres. MATERIALS AND

methodsThe results of the EUSOMA quality indicators were compared, based on pseudonymised individual records, for the periods 1 March 2020 till 30 June 2020 (first COVID-19 peak in most countries in Europe) and 1 March 2019 till 30 June 2019. In addition, a questionnaire was sent to the participating Centres for investigating the impact of the COVID-19 pandemic on the organisation and the quality of breast cancer care.

resultsForty-five centres provided data and 31 (67%) responded to the questionnaire. The total number of new cases dropped by 19% and there was a small significant higher tumour (p = 0.003) and lymph node (p = 0.011) stage at presentation. Comparing quality indicators (12,736 patients) by multivariable analysis showed mostly non-significant differences. Surgery could be performed in a COVID-free zone in 94% of the centres, COVID testing was performed before surgery in 96% of the centres, and surgical case load was reduced in 55% of the centres. Modifications of the indications for neoadjuvant endocrine therapy, chemotherapy, and targeted therapy were necessary in 23%, 23%, and 10% of the centres; changes in indications for adjuvant endocrine, chemo-, targeted, immune, and radiotherapy in 3%, 19%, 3%, 6%, and 10%, respectively.

conclusionQuality of breast cancer care was well maintained in EUSOMA breast centres during the first wave of the COVID-19 pandemic. A small but significantly higher tumour and lymph node stage at presentation was observed.

Indexed as

Breast NeoplasmsCOVID-19COVID-19 TestingFemaleHumansPandemicsSARS-CoV-2Breast neoplasmsCOVID-19Data warehousingHealthcareQuality indicatorsSARS-CoV-2Surveys and questionnaires

Identifiers

PMID36332437
PMCPMC9554010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.